PDLI - PDL BioPharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

PDL BioPharma, Inc.

932 Southwood Boulevard
Incline Village, NV 89451
United States
775-832-8500
http://www.pdl.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees87

Key Executives

NameTitlePayExercisedYear Born
Mr. John Peter McLaughlin J.D.CEO & DirectorN/AN/A1952
Mr. Peter S. GarciaVP & CFON/AN/A1962
Mr. Steffen PietzkeVP of Fin. & Chief Accounting OfficerN/AN/A1972
Mr. Christopher L. Stone J.D.VP, Gen. Counsel & Sec.N/AN/A1964
Mr. Dominique P. MonnetPresN/AN/A1961
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Corporate Governance

PDL BioPharma, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.